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I 
Research and development expenditures in  the United States have increased 
substantially i n  the past decade, rising from approximately $5 billion in 1953 to $19 
billion in 1964 [2, pp. 6 and 
and steady growth of R & D expenditures, there has been a growing public awareness 
. Perhaps a s  a reflection of both the magnitude 
of, and concern about, the possible effects of R & D expenditures on the national 
and regional economies in the United States. One issue that has often been discussed 
in recent years is the very uneven distribution of R & D activity among regions b7]. 
Because industry performs much of the nation's R & D, amounting to 73 percent in 
1963 k2, p. a, the regional distribution of R & D depends primarily on the distribu- 
tion of industrial research and thus on individual f i rm decisions about the best geo- 
graphic location of research facilities. 
This paper is a study of the geographic distribution of research activity in  the 
pharmaceutical industry. We are interested, first, in identifying the existing spatial 
pattern of pharmaceutical research and, then, in explaining a t  least some of its causes. 
"The research for this paper was supported by NASA Research Grant 
NGR-26-004-012 to the University of Missouri, Columbia, Missouri. 
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Although several studies of the economics of research and development from the point 
of view of the firm or industry have recently become available, they do not develop 
the locationa I aspects of industrial research activity. 1 
For the purposes of this paper, the pharmaceutical industry is defined to cor- 
respond to SIC Industry 283 and thus to include firms that manufacture medicine chemical, 
biological, and pharmaceutical products. These products a re  either ethical or proprietary 
drugs. Ethical products a re  advertised primarily to the health profession and, for the 
most part, a re  available to the public only through written prescription, while pro- 
prietary products are  advertised and sold directly to the public. Because a major part 
of the industry's production and sales involve ethical drugs B3, pp. 53 and 6a , we 
will view the industry primarily as  a producer of ethical products. 2 
The pharmaceutical industry is a n  oligopolistic industry with a few large and 
many small firms. In 1958 the largest 7 and 15 firms accounted, respectively, for 41 
and 61 percent of the industry's sales p, p. 3745). Pharmaceutical products may be 
divided into a number of therapeutic classes. Product competition tends to occur within 
See, for example, Minasian 171, Mansfield [6] , and Comanor p,3] . 
The National Science Foundation purportedly takes a similar point of view 
when gathering data on pharmaceutical R & D activity, in  the sense that firms that 
a re  predominantly manufucturers of proprietary drugs are  excluded from the published 
R & D data E3, p. 381. 
1 
2 
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but not among therapeutic markets and it generally takes the form of product differ- . 
entiation rather than price competition. Product differentiation in the industry, is 
achieved both through research expenditures, designed to produce new products or 
new forms of existing products, and advertising and marketing expenditures. Because 
pharmaceutical research is intended to  achieve product differentiation, research 
programs favor projects with shorter gestation periods, that is, research on new com- 
binations and dosage forms of existing drugs, rather than new drugs, and applied 
research and development rather than basic research. This preference for research 
programs with short gestation periods tends to lead to a high rate of product obsolescence 
in the industry. As a result, product differentiation cannot be maintained solely through 
advertising and marketing efforts. 
The  necessity for sizeable research and selling expenditures in  the pharrna- 
ceutical industry represents a fairly strong barrier to entry into therapeutic markets. 
Additional research expenditures are likely to be encouraged where pharmaceutical 
products a re  protected by patents since entry into a protected market requires research 
efforts to circumvent patent protection. On the other hand, the use of crass-licensing 
agreements for patented pharmaceutica I products tends to discourage research expendi- 
tures. These agreements maintain barriers to the entry of new producers and a t  the 
s a m e  time remove the motivation for research to circumvent patents. 
In  the pharmaceutical industry, then, the research decision is a profit- 
oriented decision designed to give a competitive advantage over other firms and to 
bar potential competitors. Research expenditures are financed primarily from company, 
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rather then federal government, sources of R & D funds and devoted, in large part, 
3 to applied research and development rather than basic research. 
If the nature of research in the pharmaceutical industry i s  shaped by the 
industry's market structure and the characteristics of i t s  product, i t  is to be expected 
that the geographic distribution of pharmaceutical research would also be affected i n  
this fashion. The simplest hypothesis about the location of pharmaceutical research 
i s  that research is attracted toward the location of production. In order to examine 
the applicability of this hypothesis, the spatial pattern of pharmaceutical R & D will 
be compared with the pattern of production. 
111 
In order to compare the spatial patterns of pharmaceutical research and pro- 
Employment will be used as  a measure of both duction, regional data a re  required. 
production and research. 
Data describing the state distribution of industrial R & D have only recently 
been made available by the National Science Foundation u l ,  pp. 86-88]. However, 
these data a re  not available for individual industries. 
Pharmaceutical R & D employment by states was estimated from data published 
3in 1964, 95 percent of the R & D expenditures of the pharmaceutical industry 
were financed from company funds, and 87 percent of the R & D expenditures were 
used for applied research and development DO, pp. 5 and 91 . 
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in the 1956, 1960, and 1965 editions of Industrial Research Laboratories of the 
United States , 91. This book lists pharmaceutical laboratories and their loca- 
tions, types of research, and employment of professional and supporting personnel. 
A subject index of types of research was used to identify pharmaceutical laboratories 
in the 1956 and 1960 editions. Many of the labs, listed as  performing pharmaceutical 
research, also were engaged in research on such items a s  cosmetics, insecticides, and 
other chemical products. Only those labs with at least 50 percent of their research 
in  pharmaceuticals were considered. In the case of large firms, this usually meant a 
division of the firm was used, For smaller firms, only labs with more than 50 percent 
of their activities i n  pharmaceutical research were counted. 
Data from the 1965 edition a re  m u c h  less satisfactory. Industrial laboratories 
included in this edition a re  not indexed by type of research. So, only laboratories 
from the 1956 and 1960 editions that also appeared in the 1965 edition are included 
i n  the data from the 1965 edition. In this manner,  54 labs are  included from fhe 1965 
edition; this compares unfavorably with 115 labs from the 1960 edition and 98 labs 
from the 1965 edition. The coverage of pharmaceutical laboratories i n  the 1965 
edition is less complete than in the earlier edition, and i t  appears to be biased toward 
the largest firms. Smaller labs listed in earlier editionsare not found in the 1965 
edition, however, all the pharmaceutical firms i n  Fortune's 1963-1 964 Plant  and 
Product Directory of the 1000 Largest U.S. Industrial Corporations are  listed D4-J. 
In the case of a few large pharmaceutical firms, R & D employment was 
reported for the entire f i rm in one or two of the editions, and the employment in labs 
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located in different states was not identified. When this occurred, the R & D 
employment of the firm was divided among the labs in proportion to the employ- 
ment shown in another edition. One of the largest pharmaceutical companies, 
Charles Pfizer and Co., is excluded from our analysis because its employment , was 
not reported by laboratory. 
Professional R & D employment is used as  our measure of R & D activity 
rather than total R & D employment. The National Science Foundation reports R & D 
employment i n  terms of the number of fuil-time-equivalent scientists and engineers. 
We are limited to the National Science Foundation's measure of industry R & D 
employment because of the requirement that the measures of R & D and industry 
employment relate to the s a m e  definition of the pharmaceutical industry. The only 
state employment data for the pharmaceutical industry are from the Census of Manu- 
facturers for the years, 1954, 1958, and 1963, The s a m e  definition of the pharma- 
ceutical industry i s  used for both these data and the R & D data from the National 
Science Foundation. 
The employment data gathered from the 1956, 1960, and 1965 editions appear 
to include a large part of the industry's professional R.& D employment. These data 
a re  expressed in  terms of total numbers employed as  compared to the full-time- 
equivalent measure of the employment of scientists and engineers used by the National 
Science Foundation. However, by comparing our state R & D data with the industry 
data of the National Science Foundation, a n  impression of the coverage i n  this 
analysis of the industry's R & D employment can be obtained. Following this procedure, 
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professional R & D employment in the pharmaceutical laboratories included for the 
years 1956, 1960, and 1964 in our figures accounted for approximately 80, 90, and 
77 percent, respectively, of the industry's professiona I employment and was found 4 
for 18, 22, and 12 states, respectively. 
/ 
IV 
Professional R & D employment in the pharmaceutical industry is highly con- 
centrated in a few states in the Midwest and East. The largest three and five states 
in terms of professional R & D employment accounted for approximately 50 and 70 
percent, respectively, of the industry's professional R & D employment for each of 
the years 1956, 1960, and 1964. New York with one-fourth the industry's profes- 
sional R & D employment was the first state in each year. New Jersey, Pennsylvania, 
Michigan, Indiana, and Illinois also appeared among the first five states in the three 
years. The extent to which pharmaceutical R & D employment is concentrated among 
states does not appear to have changed to any large degree from 1956 to 1964. 
We have suggested that pharmaceutical research is likely to be attracted 
toward pharmaceutical production and thus that the geographic patterns of the two 
types of activity are likely to be similar. In order to determine the applicability 
of this hypothesis, the coefficient of geographic association and the Spearman rank 
Because the total industry figures are  in terms of full-time-equivalents, these 4 
percentages somewhat overstate the actual coverage. The difference is not likely to 
be more than a few percentage poinfs, however. 
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correlation coefficient can be used to obtain some measure of the relationship 
between the spatial patterns of production and research. Since R & D employment is 
included in industry employment, the state distribution of professional R & D employ- 
ment is compared with the state distribution of industry employment less professional 
R & D employment. This procedure does not cause any significant changes in the 
resu I ts . 
The coefficient of geographic association is constructed by subtracting each 
state's percentage share of professional R & D employment from its percentage share 
of total pharmaceutical employment E, pp. 251 -254) . Either the positive or nega- 
tive differences are then summed and divided by 100. The resulting coefficient can 
range from zero, if the patterns of research and production resemble each other closely, 
to one, if the two are  completely dissimilar. The coefficients for 1956, 1960, and 
1964 were .26, .20, and .18, respectively, indicating that the geographic patterns 
of research and production a re  quite similar. 
The Spearman rank correlation coefficient is also used to compare the two 
patterns of employment with generally the same results E6, pp. 202-2121 . In  this 
case each state is ranked according to its share of R & D and industry employment 
and the two sets of state rankings compared. Rank correlation coefficients of .90, 
.91, and .95 were obtained for 1956, 1960, and 1964, which indicate a high degree 
'of association between the state patterns of research and production in the pharma- 
5 ceutica I industry. 
Since we do not know anything about the randomness of the sample of the 5 
pharmaceutical laboratories used i n  this study, no conclusions can be reached about 
the significance of the correlation coefficients. 
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V 
A high degree of association between the geographic patterns of research 
and production in the pharmaceutical industry is suggested by both measures of 
association. This does not necessarily indicate, however, that a causal relation- 
ship exists between the locations of production and research or that the causality 
runs in any particular direction. Both research and production activities could 
agglomerate quite independently of one another. 
The existing pattern of pharmaceutical research is likely to have evolved 
for reasons which a re  both dependent and independent of the locations of pharma- 
ceutical production. The most important explanations for the location of pharma- 
ceutical research appear to stem from the nature of the research product and the 
composition of inputs used for the production of pharmaceutica I research. 
The product of research i n  the pharmaceutical industry is information which 
is expected to result, in a reasonably short period of time, in the introduction and 
manufacture of new pharmaceutical products. Economies are  likely to be realized 
in the process of converting research results into the production of new drugs when 
communications can be facilitated between those involved in  research efforts con- 
cerned with product development and those involved in  the production process. For 
this reason, proximate locations of production and research a re  encouraged by the 
fact that communication flows tend to deteriorate over increasing distances. 6 
6The potential advantage of increused flows of information also encourages 
the combination of research and production i n  the Same  corporate structure; see 
Comanor p] , pp. 16-17. 
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The spatial pattern of pharmaceutical research may also be influenced by the 
composition of inputs used in the research process. Pharmaceutical research is a 
highly labor-intensive activity; in 1962 and 1963 average company expenditures for 
R 8t D labor services represented approximately 55 percent of their non-capital R 8t D 
expenditures [l, pp. 97 and 1011 . Because of the importance of labor in pharma- 
ceutical research, regions with larger supplies of professional and technical R & D 
labor skills a re  relatively more attractive as  locations for research facilities, though 
the opposite direction of causality is also possible. The labor supplies for both 
pharmaceutical production and research are  concentrated in  highly urbanized regions. 
Therefore, the agglomeration of research and production is encouraged by coincident 
sources of labor, but in this case the two types of activity tend to agglomerate for 
independent reasons. 
Compared with labor, materials and supplies play a relatively small role i n  
the production of pharmaceutical research. In 1962 and 1963, average company 
expenditures on R & B materials and supplies represented only 13 percent of their 
R & D expenditures D l ,  pp. 97 and 1013 . Because of the relatively small expendi- 
tures for these research inputs, the locations of sources of materials and supplies are  
not likely to have a very strong effect on the spatial pattern of pharmaceutical 
~ 
research. 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9,  
10. 
BI BLI OGRAPHY 
William W. Buchanan, Industrial Research Laboratories of the United States, 
Edition 12 (Washington, D.C.: Bowker Associates, Inc., 1965). 
William S. Comanor, "Research and Competitive Product Differentiation i n  
the Pharmaceutical Industry in the United States, '' Economica, Vol. XXXl 
(Nov., 1964), pp. 372-384. 
William S. Comanor, "Research and Technical Change in the Pharmaceutical 
Industry," Review of Economics and Statistics, Vol. XLVll (May, 1965), 
pp. 182-190. 
William S. Comanor, "The Drug Industry and Medical Research: The Economics 
of the Kefauver Committee Investigations, I' Journal of Business, Vol. XXXIX 
(Jan., 1966), pp. 12-18. 
Walter Isard, Methods of Regional Analysis: An lnfroduction to Regional 
Science (New York: John Wiley & Sons, 1960). 
Edwin Mansfield, "Rates of Return from Industrial Research and Development, 
Papers and Proceedings, American Economic Association, Vol . LV (May, 1965), 
pp. 310-322. 
Jom R. Minasian, "The Economics of Research and Development," The Rate 
and Direction of lnventive Activity: Economic and Social Factors, ed. Richard 
R. Nelson (Princeton, N .J .: National Bureau of Economic Research and 
Princeton Un?versity Press, 1962), pp. 93-141. 
Moody's Industrial Manual (New York: Moody's Investors Service, Inc., 
1957 to 1965). 
National Academy of Science, National Research Council, Industrial Research . 
Laboratories of the United States, Editions 10 and 11 (Washington, D.C.: 
National Accldsmy of Sciences, 1956 and 1960). 
National Science Foundation, "Basic Research, Applied Research, and 
Development in American Industry, 1964, '' Reviews of Data on Science 
Resources, No. 7 (Jan., 1966). 
11. National Science Foundation, Basic Research, Applied Research, and 
Development in  Industry, 1963 (Washington, D.C.: U.S. Government 
Printing Office, 1966). 
12. National Science Foundation, "Research Funds Used in  the Nation's 
Scientific Endeavor, 1963, " Reviews of Research on Science Resources, 
Vof . I (May, 1965). 
_.- 
13. Pharmaceutical Manufacturers Association, Prescription Drug Industry Fact 
Book (Washington, D .C .: Pharmaceutical Manufacturers Association, 1965). 
___I 
14. 1963-1964 Plant and Product Directory of the 1000 Largest U.S. Industrial 
Corporations (New York: Time, Inc., 1963). 
Sidney Siegel, Nonparametric Statistics for the Behavioral Sciences (New 
York: McGraw-Hill Book Compny, Inc., 1956). 
15. 
16. Henry Steele, "Patent Restrictions and Price Competition in  the Ethical 
Drugs Industry," Journal of Industrial Economics, Vol. X11 (July, 1964), 
pp. 198-223. 
17. U .  S. House of Representatives, Committee on Science and Astronautics, 
Subcommittee on Science, Research, and Development, Government and 
Science No. 4, "Geographic Distribution of Federal Research and Develop- 
ment Funds, I' 88th Cong . , 2nd Sess,, 1965. 
, 
